Treatment of Severe Refractory Uveitis With Intravenous Cyclophosphamide

J Rheumatol. 1994 Jan;21(1):123-5.

Abstract

Objective: We assessed the efficacy of intravenous (iv) cyclophosphamide therapy for patients with uveitis.

Methods: Eleven patients with uveitis were treated with iv cyclophosphamide. Patients were from a tertiary care, referral practice, had failed oral corticosteroid therapy, and had disease that interfered with activities of daily living.

Results: Only 5 patients benefitted and the improvement was sustained without additional immunosuppression in only 2 patients, one of whom had only mild eye disease and was receiving cyclophosphamide for a central nervous system vasculitis. Four patients worsened during the therapy.

Conclusion: Although iv cyclophosphamide may have fewer risks than daily, oral cyclophosphamide, the majority of patients with uveitis do not experience a sustained benefit from this therapeutic approach.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Cyclophosphamide / therapeutic use*
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Treatment Outcome
  • Uveitis / drug therapy*
  • Uveitis / physiopathology
  • Visual Acuity / drug effects

Substances

  • Cyclophosphamide